Analysis of DNA methylation in single circulating tumor cells

Oncogene

Volumn 36, Issue 23, 2017, Pages 3223-3231

  Pixberg, C F ^a   Raba, K ^a   Muller F ^a   Behrens, B ^a   Honisch, E ^a   Niederacher, D ^a   Neubauer, H ^a   Fehm, T ^a   Goering, W ^a   Schulz, W A ^a   Flohr, P ^b,c   Boysen, G ^b,c   Lambros, M ^b,c   De Bono, J S ^b,c   Knoefel, W T ^a   Sproll, C ^a   Stoecklein, N H ^a   Neves, R P L ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; MICRORNA; MICRORNA 141; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA429; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; CDH1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CELL ISOLATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; MCF-7 CELL LINE; MDA-MB-231 CELL LINE; METASTASIS; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SINGLE CELL ANALYSIS; BREAST TUMOR; FEMALE; GENETIC EPIGENESIS; GENETICS; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CADHERINS; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SINGLE-CELL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 85008642081     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.480     Document Type: Article

References (76)

1. Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene 2015; 35: 1216-1224.
2. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 2010; 7: 693-701.
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
4. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, et al. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011; 130: 449-455.
5. Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One 2015; 10: E0123976.
6. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-584.
7. Gires O, Stoecklein NH. Dynamic EpCAM expression on circulating and disseminating tumor cells: Causes and consequences. Cell Molr Life Sci 2014; 71: 4393-4402.
8. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-tomesenchymal transition. BMC Cancer 2012; 12: 178.
9. Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, et al. A comprehensive DNA methylation profile of epithelial-to-mesenchymal transition. Cancer Res 2014; 74: 5608-5619.
10. Jones PA. Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 2012; 13: 484-492.
11. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
12. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
13. Christoffersen NR, Silahtaroglu A, Orom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA 2007; 13: 1172-1178.
14. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
15. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283: 14910-14914.
16. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007; 67: 7972-7976.
17. Mansouri A, Spurr N, Goodfellow PN, Kemler R. Characterization and chromosomal localization of the gene encoding the human cell adhesion molecule uvomorulin. Differentiation 1988; 38: 67-71.
18. Davalos V, Moutinho C, Villanueva A, Boque R, Silva P, Carneiro F, et al. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2011; 31: 2062-2074.
19. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 275: 2727-2732.
20. Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129-144.
21. Stoecklein NH, Fischer JC, Niederacher D, Terstappen LW. Challenges for CTCbased liquid biopsies: Low CTC frequency and diagnostic leukapheresis as a potential solution. Expert Rev Mol Diagn 2015; 16: 147-164.
22. Alberter B, Klein CA, Polzer B. Single-cell analysis of CTCs with diagnostic precision: Opportunities and challenges for personalized medicine. Expert Rev Mol Diagn 2015; 16: 25-38.
23. Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol Cancer Res 2013; 11: 1248-1257.
24. Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem 2013; 59: 270-279.
25. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem 2011; 57: 1169-1177.
26. Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, et al. Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. Int J Cancer 2014; 134: 2284-2293.
27. Pixberg CF, Schulz WA, Stoecklein NH, Neves RPCharacterization of DNA methylation in circulating tumor cellsGenes (Basel) 2015; 6: 1053-1075.
28. Hayatsu H, Wataya Y, Kai K, Iida S. Reaction of sodium bisulfite with uracil, cytosine, their derivatives. Biochemistry 1970; 9: 2858-2865.
29. Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990-2997.
30. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89: 1827-1831.
31. Raizis AM, Schmitt F, Jost JP. A bisulfite method of 5-methylcytosine mapping that minimizes template degradation. Anal Biochem 1995; 226: 161-166.
32. Grunau C, Clark SJ, Rosenthal A. Bisulfite genomic sequencing: Systematic investigation of critical experimental parameters. Nucleic Acids Res 2001; 29: E65-E65.
33. Olek A, Oswald J, Walter J. A modified and improved method for bisulphite based cytosine methylation analysis. Nucleic Acids Res 1996; 24: 5064-5066.
34. Hajkova P, el-Maarri O, Engemann S, Oswald J, Olek A, Walter J. DNA-methylation analysis by the bisulfite-assisted genomic sequencing method. Methods Mol Biol 2002; 200: 143-154.
35. EpiGeneSys.eu. Tierling S, Reither S, Walter J. Bisulfite sequencing of small DNA/cell samples (PROT35) [updated 2007 November 12]. Available at: Http://www. epigenesys.eu/images/stories/protocols/pdf/20111026124522-p35.pdf.
36. Shapiro R, Braverman B, Louis JB, Servis RE. Nucleic acid reactivity and conformation. II. Reaction of cytosine and uracil with sodium bisulfite. J Biol Chem 1973; 248: 4060-4064.
37. Geuns E, De Rycke M, Van Steirteghem A, Liebaers I. Methylation imprints of the imprint control region of the SNRPN-gene in human gametes and preimplantation embryos. Hum Mol Genet 2003; 12: 2873-2879.
38. Geuns E, De Temmerman N, Hilven P, Van Steirteghem A, Liebaers I, De Rycke M. Methylation analysis of the intergenic differentially methylated region of DLK1-GTL2 in human. Eur J Hum Genet 2007; 15: 352-361.
39. Geuns E, Hilven P, Van Steirteghem A, Liebaers I, De Rycke M. Methylation analysis of KvDMR1 in human oocytes. J Med Genet 2007; 44: 144-147.
40. Neves R, Scheel C, Weinhold S, Honisch E, Iwaniuk KM, Trompeter HI, et al. Role of DNA methylation in miR-200c/141 cluster silencing in invasive breast cancer cells. BMC Res Notes 2010; 3: 219.
41. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010; 5: E8697.
42. Wiklund ED, Bramsen JB, Hulf T, Dyrskjot L, Ramanathan R, Hansen TB, et al. Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011; 128: 1327-1334.
43. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-5199.
44. Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322-22329.
45. Lombaerts M, van Wezel T, Philippo K, Dierssen JW, Zimmerman RM, Oosting J, et al. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 2006; 94: 661-671.
46. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 7416-7419.
47. Neves RP, Raba K, Schmidt O, Honisch E, Meier-Stiegen F, Behrens B, et al. Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin Chem 2014; 60: 1290-1297.
48. Polzer B, Medoro G, Pasch S, Fontana F, Zorzino L, Pestka A, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 2014; 6: 1371-1386.
49. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and nextgeneration sequencing. Cancer Res 2013; 73: 2965-2975.
50. Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al. Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res 2014; 74: 1694-1704.
51. Brambert PR, Kelpsch DJ, Hameed R, Desai CV, Calafiore G, Godley LA, et al. DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells. PLoS One 2015; 10: E0117310.
52. Farias EF, Petrie K, Leibovitch B, Murtagh J, Chornet MB, Schenk T, et al. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc Natl Acad Sci USA 2010; 107: 11811-11816.
53. Lianidou ES. Gene expression profiling and DNA methylation analyses of CTCs. Mol Oncol 2016; 10: 431-442.
54. Magbanua MJ, Park JW. Advances in genomic characterization of circulating tumor cells. Cancer Metastasis Rev 2014; 33: 757-769.
55. Schwartzman O, Tanay A. Single-cell epigenomics: Techniques and emerging applications. Nat Rev Genet 2015; 16: 716-726.
56. Hou JM, Krebs MG, Lancashire L, Sloane R, Backen A, Swain RK, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-532.
57. Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, et al. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res 2014; 16: 485.
58. Rossi E, Basso U, Celadin R, Zilio F, Pucciarelli S, Aieta M, et al. M30 neoepitope expression in epithelial cancer: Quantification of apoptosis in circulating tumor cells by CellSearch analysis. Clin Cancer Res 2010; 16: 5233-5243.
59. Larson CJ, Moreno JG, Pienta KJ, Gross S, Repollet M, O'Hara S M, et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 2004; 62: 46-53.
60. Genereux DP, Johnson WC, Burden AF, Stoger R, Laird CD. Errors in the bisulfite conversion of DNA: Modulating inappropriate-A nd failed-conversion frequencies. Nucleic Acids Res 2008; 36: E150.
61. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008; 9: 582-589.
62. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846-7854.
63. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, Schreiber M, et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005; 24: 2375-2385.
64. Grooteclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000; 19: 3823-3828.
65. Guaita S, Puig I, Franci C, Garrido M, Dominguez D, Batlle E, et al. Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression. J Biol Chem 2002; 277: 39209-39216.
66. Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, et al. Detection and phenotyping of circulating tumor cells in high-risk localized prostate cancer. Clin Genitourin Cancer 2015; 13: 130-136.
67. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res 2011; 9: 997-1007.
68. Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009; 69: 7135-7139.
69. Tsai JH, Donaher JL, Murphy DA, Chau S, Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012; 22: 725-736.
70. Tsuji T, Ibaragi S, Shima K, Hu MG, Katsurano M, Sasaki A, et al. Epithelialmesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res 2008; 68: 10377-10386.
71. Chaffer CL, Brennan JP, Slavin JL, Blick T, Thompson EW, Williams ED. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: Role of fibroblast growth factor receptor-2. Cancer Res 2006; 66: 11271-11278.
72. Allard WJ, Terstappen LW. CCR 20th Anniversary Commentary: Paving the way for circulating tumor cells. Clin Cancer Res 2015; 21: 2883-2885.
73. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 61-66.
74. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders Jr RA, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-57.
75. Polioudaki H, Agelaki S, Chiotaki R, Politaki E, Mavroudis D, Matikas A, et al. Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer. BMC Cancer 2015; 15: 399.
76. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer 2016; 16: 110-120.